DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tagamet (Cimetidine Hydrochloride) - Summary



Tagamet (cimetidine) is a histamine H2-receptor antagonist.

Tagamet (cimetidine) is indicated in:

  1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use Tagamet at full dosage for longer than 6 to 8 weeks (see Dosage and Administration - Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of Tagamet and antacids is not recommended, since antacids have been reported to interfere with the absorption of Tagamet.
  2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with Tagamet 400 mg h.s. for periods of up to 5 years.
  3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks.
  4. Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of Tagamet beyond 12 weeks has not been established (see Dosage and Administration --GERD).
  5. Prevention of upper gastrointestinal bleeding in critically ill patients.
  6. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas).

See all Tagamet indications & dosage >>


Published Studies Related to Tagamet (Cimetidine)

A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis. [2015]
Cutaneous leishmaniasis (CL) is a major world health problem, which is increasing in incidence... Our results showed that although oral cimetidine and low-dose systemic MA had less efficacy in comparison to a standard dose of systemic MA in the treatment of CL, it still can be considered as a replacement therapy in high-risk patients (such as patients with heart, kidney, and/or liver disease) under close supervision of physicians.

Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori: a randomized controlled comparative trial with cimetidine, an H2-receptor antagonist. [2010.05]
BACKGROUND AND AIMS: According to reports in Japanese patients, 1 week of Helicobacter pylori eradication therapy alone is not adequate for healing of gastric ulcers; 7-8 weeks of anti-ulcer therapy are subsequently required. We compared a gastroprotective drug, sofalcone, and an H(2)-receptor antagonist, cimetidine, in terms of promoting ulcer healing after 7 weeks of administration following 1 week of eradication therapy... CONCLUSION: Sofalcone promoted gastric ulcer healing during 7 weeks of treatment following 1 week of eradication therapy, and the healing rate was equivalent to that of cimetidine. Symptom disappearance rates were significantly better in the sofalcone group than in the cimetidine group. This may be a useful way of using a gastroprotective drug in the H. pylori era.

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. [2010.01]
OBJECTIVE: The dipeptidyl peptidase-4 inhibitor alogliptin, under development for treatment of Type 2 diabetes, primarily is excreted renally. This study investigated (1) the effect of food on alogliptin pharmacokinetics and tolerability and (2) pharmacokinetic interactions between alogliptin and metformin or cimetidine and tolerability of alogliptin when administered with either drug... CONCLUSION: Alogliptin can be administered without regard to meals and with metformin or cimetidine without the need for dose adjustment.

[Efficacy comparison between cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts] [2009.01]
BACKGROUND: Warts are epithelial proliferations on the skin and mucous membrane caused by various types of HPV. They can decrease spontaneously or increase in number and size according to patient's immune status. Cimetidine and zinc sulphate have important effects on the immune system and are used as immunomodulators in the treatment of various diseases. OBJECTIVE: To compare the efficacy of cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts... CONCLUSIONS: 10 mg/Kg/day zinc sulphate dose seems to be more effective than cimetidine for the treatment of children and adults with multiple and difficult-to-handle warts. However, the small number of patients did not enable any definitive conclusion.

Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. [2008.05]
BACKGROUND: This study aimed to assess intermittent intravenous (IV) pantoprazole for control of gastric acid and the possible prevention of upper gastrointestinal (UGI) bleeding in intensive care units (ICU) patients... CONCLUSIONS: This pilot study indicates that intermittent IV pantoprazole effectively controls gastric pH and may protect against UGI bleeding in high risk ICU patients without the development of tolerance.

more studies >>

Clinical Trials Related to Tagamet (Cimetidine)

Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients [Completed]
Among the different creatinine-based GFR predicting equations, the MDRD equation gives the best prediction in renal transplantation but does not provide the level of accuracy usually seen in renal patients with native kidneys. Blocking the tubular secretion of creatinine with an oral administration of cimetidine is likely to make creatinine a more accurate marker of GFR. We will test the hypothesis that the accuracy of the MDRD equation will be improved in renal transplant patients by incorporating into the equation a cimetidine-corrected serum creatinine value.

Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients [Recruiting]
The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI) [Completed]
This study will assess the effect of cimetidine on the pharmacokinetics (PK) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine. Additionally, this study will explore the influence of genetic variation on the PK of dexpramipexole when given with or without cimetidine.

Cimetidine Biowaivers [Recruiting]
The purpose of this research is to see if non-drug ingredients in capsules and oral solutions affect how well drugs are absorbed. This is called "bioequivalence." Medications taken by mouth, such as capsules and solutions, need to be absorbed into the body in order to do any good. Capsules and solutions contain a drug, but also contain non-drug ingredients that are called excipients or fillers. Excipients in the capsules and solutions can impact how much drug is absorbed into the body. This is called "bioINequivalence." Capsules and solutions in this research contain the drug cimetidine. This drug is being used since it has high water solubility (can dissolve in water) and low ability to be absorbed.

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body [Terminated]
The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with cimetidine.

more trials >>

Reports of Suspected Tagamet (Cimetidine) Side Effects

Drug Ineffective (8)Abnormal Dreams (2)Dialysis (2)Abortion Missed (2)Panic Reaction (2)Renal Failure Acute (2)Cerebrovascular Accident (2)Renal Impairment (2)Cerebral Infarction (2)Hemiplegia (2)more >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017